Comparison of the effects of loratadine and astemizole in the treatment of children with seasonal allergic rhinoconjunctivitis

The efficacy and safety of a once‐daily dose of loratadine 10 mg (5 mg in patients whose body weight was ≤ 30 kg) and astemizole 2 mg/10 kg body weight o.d. were compared in a 14‐day third‐party blind study. Forty‐one children (30 boys and 11 girls, aged 6–14 years) with seasonal allergic rhinoconjunctivitis entered the study. The pollen count was monitored throughout the study. A significant improvement (p < 0.01) in allergy symptoms was observed from the third day for both drugs; there was no significant difference between drugs, although loratadine led to a greater reduction in symptoms. In the astemizole group, the apparently rapid onset of drug action might by explained by reduced pollen exposure. Therapeutic response was excellent/good in 83.3% and 58.8% of the loratadine and astemizole groups, respectively. The results reported by the patients/parents were similar. Nine of the children on astemizole and four children on loratadine complained of side effects; three patients in the astemizole group were withdrawn from treatment because of adverse effects. No abnormal changes in lab values were observed in either group.